Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial
Autor: | Gérard Lledo, Benoit Samson, Dewi Vernerey, Marie-Line Garcia-Larnicol, Olivier Dupuis, Ghaouti Nabil Baba Hamed, Werner Scheithauer, May Mabro, Ahmed Khalil, Nicole Tubiana-Mathieu, Nathalie Aucoin, Jérôme Dauba, Frédéric Viret, Aimery de Gramont, Thierry André, Christophe Tournigand, Benoist Chibaudel, Yves Rinaldi, Elisabeth Carola, Christophe Louvet |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Bevacizumab Colorectal cancer medicine.drug_class business.industry medicine.disease Monoclonal antibody Primary tumor Treatment efficacy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine In patient Erlotinib business EGFR inhibitors medicine.drug |
Zdroj: | Journal of Clinical Oncology. 36:737-737 |
ISSN: | 1527-7755 0732-183X |
DOI: | 10.1200/jco.2018.36.4_suppl.737 |
Popis: | 737 Background: Primary tumor sidedness (PTS) could be a predictive maker for treatment efficacy of EGFR inhibitors monoclonal antibodies in patients with wild-type (WT) RAS metastatic colorectal cancer (MCRC), cetuximab having limited efficacy in patients with WT-RAS right-sided tumors. DREAM study demonstrated that adding erlotinib, an oral EGFR tyrosine kinase inhibitor (TKI) to bevacizumab during maintenance therapy improved clinical outcomes (RR, PFS, OS) in patients with MCRC, whatever KRAS status. The aim of this post-hoc analysis is to evaluate the clinical outcomes according to KRAS mutational status and PTS when adding erlotinib to bevacizumab maintenance therapy. Methods: PTS was retrospectively collected in patients from the DREAM phase III trial treated with bevacizumab with or without erlotinib as maintenance therapy for MCRC who have been controlled by induction therapy. The limit for the definition of PTS was splenic flexure, and rectal tumors were considered as left-sided tumors. The primary endpoint was overall survival (OS). Results: Among 452 patients who received maintenance therapy, PTS ascertainment was 84.7% (n = 383) with 265 (71.0%) patients having left-sided primary tumor and 108 (28.9%) having right-sided primary tumors (3 patients had both and tumor location was unknown in 7 patients). Median OS and treatment effect are presented in table 1. Conclusions: The greatest OS benefit of adding erlotinib to bevacizumab maintenance therapy was observed in patients with WT-KRAS and right-sided MCRC, suggesting a clinical impact of the different mechanism of action between EGFR TKI and monoclonal antibodies. Clinical trial information: NCT00265824. [Table: see text] |
Databáze: | OpenAIRE |
Externí odkaz: |